Retinal science doesn’t stop during the pandemic! Instead of presenting data in-person, Dr. Eichenbaum leverages technology to share from afar. This filming takes the place of meetings in Australia 🇦🇺!
Dr. Cohen became one of the first MD’s in Florida to place the newly FDA-approved Human Optics custom Iris today for a patient who lost their natural iris. We are proud to offer cutting edge surgery right here in Tampa Bay!
Not all approaches to treat advanced dry macular degeneration involve injections in the eye. We are enrolling the Ionis GOLDEN trial of sub-Q (under the skin) FB-LRX, an investigative drug for advanced dry AMD/Geographic Atrophy. We are hopeful to have success against dry AMD with all the bright minds working on this currently-untreatable disease!
The advanced form of Dry Macular Degeneration, known as Geographic Atrophy, is public enemy number one in retina. It affects about 1M Americans and there is no proven treatment, robbing patients good vision. We are proud to have a robust multi-study dry AMD clinical trial program, one of the largest in the Southeast, including the pivotal Phase 3 trial of Avacincaptad pegol. We are encouraged we may have a new weapon in this battle with these positive Phase 2 results. https://www.aaojournal.org/article/S0161-6420(20)30845-9/fulltext?dgcid=raven_jbs_aip_email
AAOJOURNAL.ORG
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial
Dr. Eichenbaum was inducted into the Retina Society tonight at its first virtual meeting. Grateful and humbled to be part of this group of leading retinal surgeons and researchers.
Dr. Eichenbaum is proud to be among the 2020 Retina Society inductees. Congrats to all these brilliant incoming members!
Although I miss seeing friends in the field I’m thrilled to be part of the ongoing scientific dialogue at the Virtual American Academy of Ophthalmology meeting this weekend. I’m grateful that science can advance despite being apart this year. #aao2020 #faricimab #clinicalscience #ophthalmology
Happy 👻 Halloween 🎃 from your Retina Team at RVAF!
November is Diabetes Awareness Month. We can work together to raise awareness for this public health problem! Dr. Eichenbaum had the opportunity for educational interviews in preparation for this important awareness month. https://www.wsaw.com/2020/10/22/the-importance-of-regular-eye-screenings-for-diabetes-patients/
WSAW.COM
The importance of regular eye screenings for diabetes patients
Congrats to our fantastic Dr. Cohen for his recognition as a Top Doctor in Tampa Bay Metro Magazine! We are honored to have our Doctors awarded by their peers year after year.
We are proud of Dr. Findlay for achieving another year as a Florida Top Doctor 🙌🏼 . RVAF continues to have the most awarded MD’s in the region for your retina care.
Stay tuned for an interview with Dr. Eichenbaum on HealthCentral on differentiating macular degeneration from diabetic eye disease. Here is a sample or HealthCentral's patient-centric, humanistic work to explain retina care. Enjoy! https://www.healthcentral.com/slideshow/wet-amd-questions
HEALTHCENTRAL.COM
What You Should Know About Wet AMD Treatment
More good news this morning! On the heels of positive diabetic eye disease data, there is positive macular degeneration data for the same new molecule, faricimab. We have been involved with this new treatment since Phase 2, and these late phase results may mean significantly fewer treatments needed for our patients. I am so proud of our doctors and gold-star ⭐️ clinical trial team for being part of this advance. So excited to do better for our patients and advance Retina! https://www.gene.com/media/press-releases/14894/2021-01-24/genentechs-faricimab-meets-primary-endpo
GENE.COM
Genentech: Press Releases | Sunday, Jan 24, 2021
We are grateful to our clinical study coordinators. Kimberly has worked hard to make our site the highest-recruiting to date for an ongoing wet AMD trial focused on reducing treatment burden for our patients ⭐️. We never rest when we are trying to do Retina better!
We are starting out 2021 with excitement! As the premier academic research practice in the region, we are proud to be the first in the world to administer a new intraocular injection which may reduce treatment burden and increase therapeutic efficacy for a variety of common retinal disease. We are here to advance the field for our patients and colleagues! https://www.linkedin.com/posts/asclepix-therapeutics-llc_firstinhuman-ophthalmology-retina-activity-6752217517139251200-ADm0/
LINKEDIN.COM
AsclepiX Therapeutics, Inc. on LinkedIn: #firstinhuman #ophthalmology #retina
Happy New Year from RVAF. We wish you peace and health in all aspects of life as we say so long to 2020.